Healius Ltd (ASX: HLS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Healius Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$479.25 million
P/E Ratio
55.56
Dividend Yield
0.00%
Shares Outstanding
726.13 million
Earnings per share
-0.757
Dividend per share
0.12
Year To Date Return
-24.31%
Earnings Yield
1.80%
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Healius Ltd (ASX: HLS)
Latest News
Blue Chip Shares
2 blue chip ASX 200 shares to buy according to experts
Healthcare Shares
3 ASX healthcare shares rated as buys by a leading broker
Dividend Investing
5 ASX shares trading ex-dividend next week
Share Gainers
Why Clinuvel, Dicker Data, Healius, and Uniti shares are rising today
Share Market News
ASX 200 (ASX:XJO) midday update: Uniti jumps on takeover speculation, Rio Tinto and Yancoal tumble
Broker Notes
2 ASX shares now at an awesome price for buying: expert
Share Gainers
Why Accent, Healius, PEXA, and WiseTech shares are rising today
Earnings Results
Healius (ASX:HLS) share price up 6% after tripling half year profits
Share Market News
Why this top broker just downgraded these 2 ASX healthcare shares
Coronavirus News
Why are ASX COVID test shares climbing today?
Dividend Investing
2 great value ASX dividend shares that brokers love
What is capital raising?
Frequently Asked Questions
-
Yes, Healius has historically paid two fully franked shareholder dividends a year.
-
Healius has generally paid its shareholder dividends in March/April and September/October.
-
Healius Ltd listed on the ASX on 3 July 1998.
HLS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Healius Ltd
Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.
The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres.
The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Nov 2025 | Paul Anderson | Buy | 54,431 | $47,899 |
On-market trade.
|
| 10 Nov 2025 | Katherine (Kathy) Ostin | Issued | 45,955 | $39,999 |
Director remuneration. VWAP, 45,955 Share Rights
|
| 31 Oct 2025 | Paul Anderson | Buy | 57,471 | $50,976 |
On-market trade.
|
| 29 Aug 2025 | Neil Vinson | Buy | 17,045 | $14,999 |
On-market trade. Average price
|
| 28 Aug 2025 | Katherine (Kathy) Ostin | Buy | 21,779 | $20,036 |
On-market trade. Average price
|
| 28 Aug 2025 | Katherine (Kathy) Ostin | Buy | 2,000 | $1,840 |
On-market trade. Average price
|
| 27 Aug 2025 | John Mattick | Buy | 200,000 | $182,000 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Christopher John Hall | Non-Executive Director | Sep 2025 |
Mr Hall has included roles as Chair, Non-Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong. Mr Halls current roles include Chair of BiomeBank, Non-Executive Director, Investment Committee Member and Audit Committee Member of AMP Superannuation, Non-Executive Director and Audit Committee Member of Funds SA, Investment Committee Chair of Perks Private Wealth, and Member of the Advisory Board to the Long-Term Value Fund at Tanarra Capital.
|
| Professor John Mattick | Non-Executive Director | Mar 2022 |
Professor Mattick was Chief Executive of Genomics England, which was established by the United Kingdom government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established high throughput NATA accredited DNA sequencing and genome analysis facilities. He was a member of the Australian Health Ethics Committee (AHEC) of the National Health & Medical Research Council (NHMRC) from 1997 to 2003, an advisor to the Australian Law Reform Commissions Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology. He is a member of the Risk Management Committees.
|
| Mr Paul Anderson | Chief Executive OfficerManaging Director | Mar 2024 |
Mr Anderson was appointed as Chief Executive Officer in March 2024. Prior to this, he held the position of Group Chief Financial Officer of Healius. He is an experienced business leader with a background in industries facing significant disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & New Zealand. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
|
| Professor Bruce Gregory Robinson AC | Non-Executive Director | Feb 2026 |
Prof Robinson is a physician, academic, and advisor with over 25 years experience as a leader in healthcare. In addition to being a practising endocrinologist, Professor Robinson currently serves as a Non-Executive Director of listed healthcare entities Cochlear Limited (ASX:COH) (since 13 December 2016) and Mayne Pharma Group Limited (ASX:MYX) (since 26 August 2014). He is also a Non-Executive Director of British speciality pharmaceutical company CS Pharmaceuticals Ltd (since 24 October 2024), a Senior Advisor to McKinsey & Company and an advisor to Minter Ellison. Professor Robinsons former roles include Chair of the Australian Governments taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australias peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydneys Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.
|
| Ms Kathryn (Kate) Mary McKenzie | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Ms McKenzie is a member of the Boards Risk Management Committee and People, Governance and Remuneration Committee. She is an experienced Chief Executive Officer and Non Executive Director. Her executive career included over 30 years of experience in the telecommunication and government sectors in Australia, New Zealand and Hong Kong. She was most recently the Chief Executive Officer of Chorus. Prior to this, she held several senior roles at Telstra, including Chief Operating Officer, where she oversaw the groups property portfolio, and seven years in senior roles in NSW Government, including the Department of Commerce and Department of Industrial Relations. She is a member of Chief Executive Women, has served on the Telstra Foundation.
|
| Ms Sally Evans | Non-Executive Director | Aug 2018 |
Ms Evans was appointed as a Non Executive Director. She is the Chair of the Boards People, Governance and Remuneration Committee and is a member of the Risk Management Committee. She has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region.
|
| Ms Katherine (Kathy) Ostin | Non-Executive Director | Dec 2024 |
Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice. During her 24 years with KPMG, she worked in Australia, the US, Asia and UK. She is a member of the People and Governance Committee.
|
| Mr Charlie Taylor | Non-Executive Director | Mar 2023 |
Mr Taylor has over 30 years of experience in international advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australias private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. He initiated multiyear research efforts on healthcare, COVID response, productivity and innovation and has published research articles and reports on healthcare reform lessons from around the globe. He is currently a part time senior board advisor at McKinsey for the Health and Public Sector practice, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. He is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. He is a member of both the People and Governance Committees.
|
| Mr Steven Rubic | Non-Executive Director | Dec 2025 |
Mr Rubic will bring to the Board 25 years of executive leadership in healthcare. He has held CEO positions at St Vincents and Mater Health Sydney, I-MED Radiology Network and Healthscope. He is also a Non-Executive Director. Mr Rubic is currently a Non Executive Director of the Mater Hospitals Group, Pacific Smiles Group Limited (ASX:PSQ) and Catholic Healthcare Limited. He is also Deputy Chair of TPG private equity owned InvoCare.
|
| Hon Andrew Peter Thomson | Company Secretary | Oct 2025 |
-
|
| Ms Kylie Brown | Company Secretary | May 2025 |
-
|
| Puneet Nagi | Chief Operating Officer |
-
|
|
| Andrew Peter Thomson | Company Secretary |
-
|
|
| Kylie Brown | Company Secretary |
-
|
|
| Rodney Rudling | Group Executive Clinical Integration |
-
|
|
| Anthea Muir | Group Executive Customer & Commercial |
-
|
|
| Prasad Arav | Group Executive Digital & Technology and Strategy |
-
|
|
| Arjun Narang | Group Executive Operations |
-
|
|
| Paula Bayliss | Group Executive People & Culture |
-
|
|
| Kylie Brown | Group General Counsel Company Secretary and Chief Risk Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 222,504,649 | 30.64% |
| Citicorp Nominees Pty Limited | 195,963,913 | 26.99% |
| J P Morgan Nominees Australia Pty Limited | 77,855,084 | 10.72% |
| BNP Paribas Noms Pty Ltd | 38,424,201 | 5.29% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Supercorp A/C> | 11,786,784 | 1.62% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 11,238,922 | 1.55% |
| Argo Investments Limited | 10,874,452 | 1.50% |
| First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> | 9,181,310 | 1.26% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 3,309,503 | 0.46% |
| Lsnd Pty Ltd <Lsnd A/C> | 2,787,659 | 0.38% |
| Rinrim Pty Ltd | 2,497,161 | 0.34% |
| Anacacia Pty Ltd <Wattle Fund A/C> | 2,450,000 | 0.34% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,267,035 | 0.31% |
| Ubs Nominees Pty Ltd | 2,124,074 | 0.29% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 2,076,697 | 0.29% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 1,992,066 | 0.27% |
| Gsa Custodians Pty Ltd <The Gsa Global Unit A/C> | 1,250,000 | 0.17% |
| Mr Edgard Zoghbi | 1,200,000 | 0.17% |
| Mr William Alan Cosgrove + Mrs Joan Iris Cosgrove <Hawthorn Super Fund A/C> | 1,000,000 | 0.14% |
| Ocean Capital Pty Limited | 1,000,000 | 0.15% |
